COVID-19 vaccination coverage among adolescents aged 12–17 years in three provinces of eastern China: A cross-sectional survey, 2021

Taishun Li†, Ruowen Qi†, Bingwei Chen‡, Yuqian Luo†, Wenjun Zhang§, Yi-Hua Zhou‡* and Biyun Xu‡*

High vaccination coverage is essential to prevent and control the spread of the COVID-19 epidemic. Currently, the real-world acceptance of COVID-19 vaccines among adolescents aged 12–17 years in China has not been reported. We aimed to assess the acceptance rate of COVID-19 vaccination among adolescents in eastern China and to identify factors associated with the intention to get vaccinated against COVID-19. We conduct a cross-sectional questionnaire survey among adolescents from three provinces in the eastern part of China from 16 August to 28 October 2021. The questionnaires were distributed to 2,100 students, and 2,048 students completed the questionnaires. The results showed that 98.4% (2,016/2,048) of adolescents had received at least one dose of the COVID-19 vaccine and 1.6% (32/2,048) declined the vaccination. The participants from rural districts, or whose parents were vaccinated, were more likely to accept the vaccine. The main reason for declining vaccination was worry about vaccine safety (25%). The main adverse event after the vaccination was pain at the injection site. In conclusion, the vaccine coverage rate reached 98.4% among the adolescents in this study, which met the criteria for herd immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The high vaccination rate is beneficial to the prevention and control of the COVID-19 pandemic.

KEYWORDS
COVID-19 vaccine, cross-sectional, vaccination rate, adolescent, China

Introduction

First occurred at the end of 2019, the COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a pandemic by March 2020 (1). The disease has spread worldwide, instigating a pandemic causing more than 533 million confirmed cases and leading to more than 6.3 million deaths worldwide based on the WHO weekly epidemiological update as of June 16, 2022 (2). The pandemic of
COVID-19 has become a major threat to global public health, resulting in a global economic downturn and social panic (3). In addition, the pandemic has disrupted some normal medical activities such as pregnancy and childbirth (4–6). In response to the serious global impacts of COVID-19, the vaccine has become one of the most effective strategies for ending the pandemic (7, 8). There is evidence that the vaccine can not only provide direct immunity to the vaccinated individuals but also reduce infections among the unvaccinated individuals by building herd immunity from large-scale coverage of the population with immunity (9).

China has developed various COVID-19 vaccines, mainly composed of inactivated SARS-CoV-2 (10). The efficacy and safety of the vaccines have been investigated in phase 3 clinical trials (11). The vaccines have been widely used in adults in China since December 2020, and the inactivated COVID-19 vaccines have also been approved for WHO emergency use listing (12). Recently, studies showed that COVID-19 vaccination alleviated the disease severity caused by wild-type as well as variants of SARS-CoV-2 (13, 14). At the initial phase of vaccination against COVID-19, the vaccines were exclusively applied to adults (≥18 years old) peoples, since the disease causes severe health impacts in adults with relatively high mortality, yet it is relatively mild in adolescents and children (15). However, with the recent global COVID-19 pandemic, especially after the delta variant had become the main transmitted strain, an increasing number of infection events reminded people to be vigilant about the spread of COVID-19 among children and adolescents (15, 16). Since July 2021, the vaccination for children and adolescents has been implemented in China, and the vaccines administered for adolescents are composed of inactivated SARS-CoV-2 (Sinovac Coronavac or Sinopharm BBIBP-CorV, China).

Adolescents aged 12–17 years are of school age, and the coverage of vaccination is essential to prevent and control the spread of SARS-CoV-2 in schools. The success of herd immunity will depend on the vaccination rate. However, numerous factors could affect the vaccination rate for children and adolescents during pandemics, such as parents’ opinions, school policies, consideration of vaccine safety, and others (17, 18). Hence, it is crucial to know the true vaccination rate among adolescents and to explore the associated factors with the acceptability of the COVID-19 vaccine.

The objective of this study was to assess the actual acceptance rate of the COVID-19 vaccine among adolescents in three provinces of eastern China and to identify factors associated with the intention to get vaccinated against COVID-19 in children and adolescents. Understanding the actual vaccination rate and the factors associated with the vaccination intention among adolescents may support government and public health officials to find better ways to persuade people to get vaccinated and finally reach herd immunity to SARS-CoV-2.

Materials and methods

Subjects and procedures

We performed a cross-sectional survey, from 16 August to 28 October 2021, on the real-world acceptance of COVID-19 vaccination among adolescents in the eastern region of China. Since high school students in China are usually aged 12–17 years, we distributed the questionnaires among the students in high schools. Based on the economic situation, the six provinces in the eastern part of China can be generally divided into high (Jiangsu and Zhejiang), middle (Shandong and Fujian), and low (Anhui and Jiangxi) levels of economic development. We selected one province from each level, namely Jiangsu, Fujian, and Anhui. In each province, we selected one school from urban areas and one school from rural areas. Students were selected using a cluster sampling method, and once their schools were included in the study, all students were given questionnaires. The students who participated in this survey were informed at the beginning of the questionnaires, as the statement “If you are willing to participate in this survey, this means that you like to give informed consent” is presented at the top of the questionnaire form (see Supplementary File 1). The parents/legal guardians received notices about the survey before it started. The protocol was approved by the Ethics Committee of the Nanjing Drum Tower Hospital (2021-462-01).

Survey design and pre-testing

The questionnaire was formulated based on the previous reports (17–24) and the opinion of experts in infectious diseases. Before the actual survey, we conducted a small-scale pre-survey on the target population and modified the survey questions and layout format after the feedback from the participants.

Measures

The questionnaire covered: (1) demographic characteristics, (2) attitudes toward vaccine, (3) acceptance of COVID-19 vaccine, and (4) adverse events after vaccination. The survey objective was to understand adolescents’ opinions on the COVID-19 vaccine and the actual vaccination rate. There was one question designed to calculate the acceptance rate of the COVID-19 vaccine: We asked the respondents to answer the question “Have you accepted the COVID-19 vaccine?” followed by an open-ended question “Why?” or “Why not?,” with a free text box. An additional text file shows the questionnaire in more detail (see Supplementary File).
Data analysis

Basic descriptive statistics and frequencies were used to describe all variables. Univariate analysis was conducted to determine factors associated with vaccination acceptance: Mann-Whitney test for comparing non-normal continuous variables, independent t-test for comparing normally distributed continuous variables, and Chi-square test or Fisher’s exact test for categorical variables. Multivariate logistic regression analysis was also used to estimate the adjusted odds ratio (OR) of vaccination, using all the variables that showed significance ($p < 0.05$) in the univariate analysis. All analyses were conducted with R version 4.0.4. $p \leq 0.05$ was considered statistically significant.

Results

Characteristics of participants

The questionnaires were distributed to 2,100 target students, and a total of 2,048 (97.5%) responded. Figure 1 shows the flow chart of study participants. All results are analyzed based on the 2,048 participants who completed the survey questionnaire. The mean age was 14.5 years (range 12–17 years), more than half (53.4%) were aged 15–17 years, and 48.8% of them were men. Most participants (60.5%) were from rural areas, and 43.5% of participants were in senior high school. The demographic information of participants is presented in Table 1.

Overall, 2,016 (98.4%) participants accepted the COVID-19 vaccine, and 32 (1.6%) participants did not. Of the 2,016 vaccinated participants, 1,918 (95.1%) completed the second dose, and 98 (4.9%) did not receive the second dose because the time intervals were < 2 weeks. The results of the univariate analysis between the vaccinated and unvaccinated groups were summarized in Table 2. The results showed that the acceptance of COVID-19 was associated with the district, willingness for vaccination, and whether the parents were vaccinated. Table 3 shows the results of multivariable binary logistic regression analysis on the factors associated with vaccine acceptance. The results indicated that the participants from rural districts or parents who were vaccinated were more likely to accept the vaccine.

Reasons for acceptance or decline of the COVID-19 vaccination

The detailed reasons for acceptance or decline of COVID-19 vaccination are presented in Table 4. The results showed that 70.6% of the vaccinated participants took the vaccine based on their own decision without a specific reason. The two other main reasons for acceptance of the COVID-19 vaccination were requested by the school manager (14.6%) and encouraged by family members (11.6%). On the other hand, worry about vaccine safety accounted for 25% (8/32) of those who declined the vaccination.
TABLE 1  Participant characteristics (n = 2,048).

| Characteristic       | n (%)  |
|----------------------|--------|
| Age, y (n = 2,048)*  |        |
| Gender               |        |
| Male                 | 998 (48.8) |
| Female               | 1,047 (51.2) |
| Province (n=2,048)   |        |
| Jiangsu              | 972 (47.5)  |
| Anhui                | 603 (29.4)  |
| Fujian               | 473 (23.1)  |
| Race (n = 2,045)     |        |
| Han                  | 1,995 (97.6) |
| other                | 50 (2.4)  |
| District (n = 2,020) |        |
| Urban                | 797 (39.5)  |
| Rural                | 1,223 (60.5) |
| Education school (n = 2,048) |        |
| Junior high school   | 1,157 (56.5) |
| Senior high school   | 891 (43.5)  |

*Unless otherwise indicated, data are the number (percentage) of survey respondents.

Self-reported adverse events in vaccinated participants

The self-reported adverse events in vaccinated participants are shown in Table 5. Of the 2016 vaccinated participants who completed the first vaccine dose, 433 (21.5%) reported one or more adverse events, with 0.8% (17/2,016) adverse events requiring treatment and 1.4% (29/2,016) adverse events affecting the study and life. Of the 1,918 vaccinated participants who accepted the second vaccine dose, 396 (20.6%) had adverse events. Table 6 presents the 10 common adverse events in the vaccinated participants, and the most common adverse event after either the first or second dose was pain at the injection site.

Discussion

In this cross-sectional study among adolescents between 12 and 17 years in three provinces of the eastern part of China, the majority (98.5%) of adolescents had received at least one dose of the COVID-19 vaccine, and 93.4% of adolescents took the second dose. The vaccination rate in teenagers is higher than that (70.1–86.2%) in adults in China (25–27), and that (42.4%) in adolescents in the USA (28). Independent factors associated with high uptake included the rural district, willingness for vaccination, and parents who were vaccinated.

The results showed that the vaccination rate in students is very high (98.5%), indicating that the school requirement of vaccination before school enrolling helps to increase the vaccination rate. Adolescents aged 12–17 years are in junior or senior high school age, and learning is the most important part of their life. However, their study life was once severely disrupted due to the epidemic of COVID-19. Higher levels of anxiety were reported in adolescents who had concerns about the quality of their education because of long-term online learning (17). Hence, adolescents were more likely to follow the school regulations to accept the COVID-19 vaccination.

Our study reflected that the adolescents whose parents got vaccinated were more likely to accept the vaccine. This demonstrated that parents' attitudes and behaviors have a great influence on adolescents' willingness to receive the vaccine against COVID-19 (29), which highlights the need for publicizing parents about COVID-19 vaccination for increasing the willingness of adolescents in the future. The results showed that the adolescents living in rural areas had a higher vaccination rate, compared with those living in urban areas. This could be the reason that the participants in cities were concerned more about the vaccine safety and effectiveness because they were exposed to different information about the COVID-19 vaccination from various sources, which gave them more uncertainty about the vaccination.

For increasing the vaccination rate, two of the six schools in our survey directly set up vaccination stations for COVID-19 in the school. This method has many advantages for the COVID-19 vaccination campaign. On the one hand, centralized vaccination on campus facilitates students and increases their enthusiasm for vaccination. Students who are initially afraid of vaccination may dispel their concerns when they are encouraged by classmates and teachers on-site, which improves the vaccination rates. On the other hand, the concentrated medical observation after vaccination is conducive to discovering the adverse events of the vaccine in time and can make a better assessment of the safety of the vaccine in adolescents. Previous studies also indicated that vaccine administration on-site at schools is an effective method to improve adolescent vaccination rates (28).

The main reason for vaccine hesitancy among unvaccinated participants included the concern about vaccine safety and effectiveness. Our results are in agreement with the findings in the vaccination intention surveys, in which the most critical reason for the decline of the COVID-19 vaccination is the concern for the safety and effectiveness of the vaccine (30–34). This highlights the need for the government to take measures to publicize the effectiveness and safety of vaccines. In this study, the self-reported adverse events occurred in 21.5% of vaccinated participants after the first dose and 20.6% after the second dose, lower than that reported in adults (35–37). Moreover, the vast majority of subjects with adverse events just had mild adverse events that did not affect their life.
TABLE 2  Univariate analysis for factors associated with COVID-19 vaccine acceptance.

|                                | Not vaccinated | Vaccinated | p   |
|--------------------------------|----------------|------------|-----|
|                                | n   | %          | n   | %    |     |
| Overall                        | 32  | 1.6        | 2,016 | 98.4 | 0.070 |
| Age group (year)               |     |            |      |      |      |
| 12–14                          | 20  | 62.5       | 935  | 46.4 | 0.070 |
| 15–17                          | 12  | 37.5       | 1,081 | 53.6 |      |
| Gender                         |     |            |      |      | 0.826 |
| Male                           | 15  | 46.9       | 983  | 48.8 |      |
| Female                         | 17  | 53.1       | 1,030 | 51.2 |      |
| District                       |     |            |      |      | 0.007 |
| Rural                          | 12  | 37.5       | 1,211 | 60.9 |      |
| Urban                          | 20  | 62.5       | 777  | 39.1 |      |
| Worry about vaccine safety     |     |            |      |      | 0.131 |
| Worry                          | 8   | 25.8       | 311  | 15.5 |      |
| No worry                       | 23  | 74.2       | 1,702 | 84.5 |      |
| Confidence for vaccine effectiveness |     |            |      |      | 0.668 |
| Confident                      | 29  | 93.6       | 1,913 | 95.0 |      |
| No confidence                  | 2   | 6.4        | 101  | 5.0  |      |
| Willingness for vaccination    |     |            |      |      | 0.001 |
| Yes                            | 27  | 87.1       | 1,954 | 97.1 |      |
| No                             | 4   | 12.9       | 59   | 2.9  |      |
| Medical workers in the family  |     |            |      |      | 0.240 |
| Direct relatives               | 4   | 12.9       | 158  | 8.0  |      |
| Other relatives                | 9   | 29.0       | 399  | 20.2 |      |
| No                             | 18  | 58.1       | 1,414 | 71.8 |      |
| Someone in the family participates in COVID-19 prevention and control work |     |            |      |      | 0.920 |
| Yes                            | 6   | 19.4       | 374  | 18.6 |      |
| No                             | 25  | 80.6       | 1,632 | 81.4 |      |
| Whether the parents are vaccinated |     |            |      |      | 0.003 |
| Both vaccinated                | 24  | 77.4       | 1,868 | 92.8 |      |
| Neither vaccinated             | 2   | 6.5        | 13   | 0.7  |      |
| One of two vaccinated          | 5   | 16.1       | 132  | 6.5  |      |
| Is life affected by the COVID-19 |     |            |      |      | 0.151 |
| Seriously affected             | 7   | 22.6       | 265  | 13.2 |      |
| Affected but not serious       | 11  | 35.5       | 1,025 | 50.9 |      |
| No effect                      | 13  | 41.9       | 722  | 35.9 |      |

and did not require treatment. Thus, this study provided evidence that inactivated COVID-19 vaccines are highly safe in adolescents.

There are some limitations in this study. First, we only investigated students and did not survey the individuals of the same age who did not go to school; thus, it remains unclear if our findings are generalizable to general adolescents. However, the school enrollment rates of junior and senior high schools in the three provinces are all above 90% (38). Second, all the adverse events were self-reported and not real-time monitored. The survey subjects were all minors and had a low level of awareness of the adverse events in the questionnaire, which might be subject to reporting bias. Hence, the name of the proprietary adverse event was explained in a popular way in the questionnaire to facilitate the understanding of the respondents. Third, since this study only evaluated the vaccination rates during the first 2 months of the program, the vaccination coverage might have increased with the popularization of the COVID-19 vaccination. Thus, long-term follow-up surveys are required to estimate the change
TABLE 3 Factors associated with COVID-19 vaccine acceptance expressed with odds ratio, in multivariate binary logistic regression.

| Factors                          | β    | SE   | OR (95% CI)     |
|----------------------------------|------|------|-----------------|
| District                         |      |      |                 |
| Rural                            | Ref  | -    | -               |
| Urban                            | -0.85| 0.39 | 0.43 (0.20–0.92) |
| Willingness for vaccination      |      |      |                 |
| No                               | Ref  | -    | -               |
| Yes                              | 1.14 | 0.58 | 3.12 (1.01–9.66)* |
| Whether the parents are vaccinated|      |      |                 |
| Neither vaccinated               | Ref  | -    | -               |
| Both vaccinated                  | 2.09 | 0.81 | 8.10 (3.67–19.35)* |
| One of two vaccinated            | 1.38 | 0.90 | 3.96 (0.68–23.10) |

*p < 0.05.

TABLE 4 Reasons for acceptance or decline of COVID-19 vaccination in participants.

| Reasons                                                   | n (%) |
|-----------------------------------------------------------|-------|
| Acceptance of COVID-19 vaccination (n=2,016)               |       |
| Totally own decision, no specific reason                  | 1,411 | (70.6) |
| Consulted the scientific literature                      | 216   | (10.8) |
| Encouraged by family members                             | 231   | (11.6) |
| Encouraged by teachers                                   | 210   | (10.5) |
| Encouraged by friends                                    | 104   | (5.2)  |
| Encouraged by doctors                                    | 57    | (2.9)  |
| Encouraged by propaganda News                             | 101   | (5.1)  |
| Requested by School manager                              | 291   | (14.6) |
| Unwilling to, but followed school arrangement             | 60    | (3.0)  |
| Others                                                    | 130   | (6.5)  |
| Decline the COVID-19 vaccination (n=32)                   |       |
| Not willing to without reason                             | 4     | (13.3) |
| Not willing to, but with the excuse such as toothache or cold | 1     | (3.3)  |
| Worried about the efficacy of the vaccine                 | 2     | (6.7)  |
| Worry about the short-term protection (3–6 months)        | 2     | (6.7)  |
| Worry about the vaccine safety                            | 1     | (3.3)  |
| Worry about political involvement                        | 2     | (6.7)  |
| Influenced by parents or relatives                        | 1     | (3.3)  |
| Influenced by friends or teachers                         | 0     | (0.0)  |
| Influenced by Internet                                   | 0     | (0.0)  |
| Worry about the safety without own chronic diseases       | 2     | (6.7)  |
| Worry about the safety because of own chronic diseases    | 5     | (16.7) |
| Willing to take, but declined by vaccination staff        | 6     | (20.0) |
| Others                                                    | 3     | (9.3)  |

TABLE 5 Self-reported Adverse events in vaccinated participants.

| Variables                                    | Dose 1, n (%) | Dose 2, n (%) | Both, n (%) |
|----------------------------------------------|---------------|---------------|-------------|
| Self-reported Adverse events                 |               |               |             |
| Completed the first dose (n=2,016)           | 433 (21.5)    | -             | -           |
| Completed the second dose (n=1,918)          | 419 (21.9)    | 396 (20.7)    | 284 (14.8)  |
| Adverse events requiring treatment           |               |               |             |
| Completed the first dose (n=2,016)           | 17 (0.8)      | -             | -           |
| Completed the second dose (n=1,918)          | 15 (0.8)      | 13 (0.7)      | 6 (0.3)     |
| Adverse events affecting life                |               |               |             |
| Completed the first dose (n=2,016)           | 29 (1.4)      | -             | -           |
| Completed the second dose (n=1,918)          | 26 (1.4)      | 23 (1.2)      | 12 (0.6)    |

TABLE 6 Top 10 incidences of adverse events after vaccination.

| Self-reported side effects                        | n (%) |
|---------------------------------------------------|-------|
| After the first dose (n=2,016)                     |       |
| Pain at the injection site                         | 281   | (13.9) |
| Local stabbing pain in the arm                     | 93    | (4.6)  |
| Redness and swelling at the injection site         | 58    | (2.9)  |
| Feeling weak after injection                       | 57    | (2.8)  |
| Delayed Menstruation (only for female)             | 41    | (2.0)  |
| Insomnia                                           | 40    | (2.0)  |
| Dizziness                                          | 38    | (1.9)  |
| Loss of appetite                                   | 37    | (1.8)  |
| Headache                                           | 36    | (1.8)  |
| Early menstruation (only for female)               | 29    | (1.8)  |
| After the second dose (n=1,918)                    |       |
| Pain at the injection site                         | 273   | (14.2) |
| Local stabbing pain in the arm                     | 82    | (4.3)  |
| Redness and swelling at the injection site         | 48    | (2.5)  |
| Feeling weak after injection                       | 45    | (2.4)  |
| Loss of appetite                                   | 36    | (1.9)  |
| Dizziness                                          | 34    | (1.8)  |
| Delayed Menstruation (only for female)             | 34    | (3.4)  |
| Early menstruation (only for female)               | 33    | (3.3)  |
| Headache                                           | 31    | (1.6)  |
| Insomnia                                           | 30    | (1.6)  |

in actual acceptance of the COVID-19 vaccine in adolescents. Fourth, the acceptance of vaccination in this study might be influenced by the enforced regulation in the schools and this could be different in different schools. Lastly, our study only selected three provinces in the eastern part of China, and only two schools were selected in each province, which might have some selection bias.
Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by Ethics Committee of the Nanjing Drum Tower Hospital. Written informed consent from the participants’ legal guardian/next of kin was not required to participate in this study in accordance with the national legislation and the institutional requirements.

Author contributions

Conceptualization: TL, RQ, BX, and Y-HZ. Methodology and resources: BX and TL. Validation: BX, BC, and TL. Formal analysis: RQ. Investigation: BX, TL, RQ, YL, and WZ. Data curation: TL and RQ. Writing—original draft preparation: TL. Writing—review and editing, project administration, and supervision: BX and Y-HZ. All authors contributed to the article and approved the submitted version.

Funding

This research was funded by Jiangsu Innovative and Entrepreneurial Talent Programme (Grant Number: JSSCBS20211510).

References

1. Thanh Le T, Andreadakis Z, Kumar A, Gómez RR, Tollefsen S, Saville M, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. (2020) 19:505–6. doi: 10.1038/d41573-020-00073-5
2. COVID-19 Weekly Epidemiological Update Edition 96. (2022). Available online at: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-96-15-2022 (accessed June 16, 2022).
3. Alagoz O, Sethi AK, Patterson BW, Churpek M, Safdar N. Effect of timing of and adherence to social distancing measures on COVID-19 burden in the United States: a simulation modeling approach. Ann Intern Med. (2021) 174:50. doi: 10.7326/M20-4096
4. Zhao Y, Zou L, Dong MH, Liu XX, Liu YL, Zhu JW, et al. Challenges for obstetricians and the countermeasures of COVID-19 epidemic. Matern Fetal Med. (2020) 2:68–71. doi: 10.1097/01.MFM.0000000000000046
5. Nieto-Calvache AJ, Padilla I, Tabares-Blanco MF, López-Girón MC, Vergara Galliadi LM. Fear is the path to the dark side: unsafe delivery, one of the consequences of fear of the SARS-CoV-2 pandemic, a case report. Matern Fetal Med. (2021) 3:292–4. doi: 10.1097/01.MFM.0000000000000112
6. Fakhriani M, Anwar S, Yufika A, Bakhtiari B, Wardiani E, Winardi W, et al. Disruption of childhood vaccination during the COVID-19 pandemic in Indonesia. Narra J. (2021) 1:e7. doi: 10.52225/narraj.v1i1.7
7. Noushad M, Nassani MZ, Alsahlami AB, Koppolu P, Niazi FH, Samran A, et al. COVID-19 vaccine intention among healthcare workers in Saudi Arabia: a cross-sectional survey. Vaccines. (2021) 9:835. doi: 10.3390/vaccines9080835
8. Goldman RD, Yan TD, Selier M, Parra Cotanda C, Brown JC, Klein EL, et al. Caregiver willingness to vaccinate their children against COVID-19: cross sectional survey. Vaccine. (2020) 38:7668–73. doi: 10.1016/j.vaccine.2020.09.084
9. Fine P, Eames K, Heymann DL. “Herd immunity”: a rough guide. Clin Infect Dis. (2011) 52:911–6. doi: 10.1093/cid/cir007
10. Baraniuk C. What do we know about China’s covid-19 vaccines? Brit Med J. (2021) 373:n912. doi: 10.1136/bmj.n912
11. Tanriver MD, Doganay HL, Akova M, Güner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole-virus SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. (2021) 398:213–22. doi: 10.1016/S0140-6736(21)01429-X

Acknowledgments

The authors would like to thank Yikun Chen from Nanjing Foreign Language School Xianlin Campus, Lin Lu from Nanjing Zhonghua Junior High School, Xiangjing Bao from Fujian Minqing First Junior High School, and Mingchuang Liao from Fujian Datian Meishan Junior High School for their supports in the investigation.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2022.919190/full#supplementary-material

SUPPLEMENTARY FILE 1
A questionnaire on COVID-19 vaccination among adolescents aged 12 to 17 in three provinces: Anhui, Jiangsu, and Fujian, China, 2021.
12. Anonymous. Chinnís COVID-19 vaccine approved for WHO emergency use listing. J Bactaf Biosecur. (2021) 5:56. doi: 10.1016/j.jacc.2021.06.001

13. Li J, Jiang N, Zeng QL, Zhang Y, He X, Chu Y, et al. The epidemiological, clinical features, and outcomes of imported Chinese COVID-19 mRNAs following inactivated vaccines injection. Infect Drug Resist. (2022) 15:2115–25. doi: 10.2147/IDR.S356460

14. Zeng QL, Li YJ, Yang J, Jiang ZY, Huang S, Li WZ, et al. Clinical characteristics of omicron SARS-CoV-2 variant infection after Non-mRNA-based vaccination in China. Front Microbiol. (2022). 33:3899. doi: 10.3389/fmicb.2022.991826 [Epub ahead of print]

15. CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children-United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep. (2020) 69:422–6. doi: 10.15585/mmwr.mm6914e4

16. Moeller KE, Meeks M, Reynolds I, Douglass M. Implementation and outcomes of COVID-19 vaccinations at a child and adolescent psychiatric hospital. J Am Acad Child Adolesc Psychiatry. (2021) 60:1332–4. doi: 10.1016/j.jaac.2021.08.018

17. Saddik B, Hussein A, Albarnia A, Elbarazi I, Al-Shujairi A, Temsah MH, et al. The psychological impact of the COVID-19 pandemic on adults and children in the United Arab Emirates: a nationwide cross-sectional study. BMC Psychiatry. (2021) 21:224. doi: 10.1186/s12888-021-03231-2

18. Scherer AM, Gedlinske AM, Parker AM, Gidengil CA, Askelson NM, Petersen CA, et al. Acceptability of adolescent COVID-19 vaccination among adolescents and parents of adolescents-United States, April 15-23, 2021. MMWR Morb Mortal Wkly Rep. (2021) 70:997–1003. doi: 10.15585/mmwr.mm7028e1

19. Park H, Yun KW, Kim KR, Song SH, Ahn B, Kim DR, et al. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of mRNA COVID-19 vaccine in Korean children: a multicenter study. J Korean Med Sci. (2021) 36:e232. doi: 10.3345/jkms.2021.36.e232

20. Lin Y, Hu Z, Zhao Q, Alias H, Danae M, Wong LP. Understanding COVID-19 vaccine demand and hesitancy: a nationwide online survey in China. PLoS Negl Trop Dis. (2020) 14:e08961. doi: 10.1371/journal.pntd.008961

21. Lazarus JV, Ratan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al. A global survey of potential of a COVID-19 vaccine. Nat Med. (2021) 27:325–8. doi: 10.1038/s41591-021-01124-4

22. Dorot AA, Eisenbach N, Taiber S, Morozov NG, Mizrachi M, Zigrin A, et al. Vaccine hesitancy: the next challenge in the fight against COVID-19. Eur J Epidemiol. (2020) 35:775–9. doi: 10.1007/s10654-020-00671-y

23. Solis Arez JS, Warren SS, Meriggi NF, Scacco A, McMurry N, Voors M, et al. COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries. Nat Med. (2021) 27:1385–94. doi: 10.1038/s41591-021-01122-5

24. Omer SB, Benjamin RM, Brewer NT, Buttener AM, Callaghan T, Caplan A, et al. Promoting COVID-19 vaccine acceptance: recommendations from the lancet commission on vaccine refusal, acceptance, and demand in the USA. Lancet. (2021) 398:2186–92. doi: 10.1016/S0140-6736(21)02057-1

25. Xu B, Gao X, Zhang X, Hu Y, Yang H, Zhou YH. Real-world acceptance of COVID-19 vaccines among healthcare workers in perinatal medicine and Obstetrics. Vaccines. (2021) 9:704. doi: 10.3390/vaccines9070704

26. Zheng Y, Shen P, Xu B, Chen Y, Luo Y, Dai Y, et al. COVID-19 vaccination coverage among healthcare workers in obstetrics and gynecology during the first three months of vaccination coverage: a 19-vaccination study in Jiangsu province, China. Hum Vaccin Immunother. (2021) 17:4946–53. doi: 10.1080/21645515.2021.1997297

27. Huang W, Shao X, Wagner AL, Chen Y, Guan B, Boulton ML, et al. COVID-19 vaccine coverage, concerns, and preferences among Chinese ICU clinicians: a nationwide online survey. Expert Rev Vaccines. (2021) 20:1361–7. doi: 10.1080/14760584.2021.1971523

28. Murphy BP, Zell E, Saelee R, Murphy N, Meng L, Meador S, et al. COVID-19 vaccination coverage among adolescents aged 12-17 Years-United States, December 14, 2020-July 31, 2021. MMWR Morb Mortal Wkly Rep. (2021) 70:1206–13. doi: 10.15585/mmwr.mm7031e1

29. Bell S, Clarke R, Mounier-Jack S, Walker JL, Paterson P. Parents' and guardians' views on the acceptability of a future COVID-19 vaccine: a multi-methods study in England. Vaccine. (2020) 38:7789–98. doi: 10.1016/j.vaccine.2020.10.027

30. Ginollí E, Sosa Y, Atici S, Engin M, Yerliחלש O, Kasap T, et al. Pediatricians’ COVID-19 experiences and views on the willingness to receive COVID-19 vaccines: a cross-sectional survey in Turkey. Hum Vaccin Immunother. (2021) 17:2389–96. doi: 10.1080/21645515.2020.1896319

31. Li XH, Chen L, Pan QN, Liu J, Zhang X, Yi J, et al. Vaccination status, acceptance, and knowledge toward a COVID-19 vaccine among healthcare workers: a cross-sectional survey in China. Hum Vaccin Immunother. (2021) 17:4065–73. doi: 10.1080/21645515.2021.1957415

32. Chen M, Li Y, Chen J, Wen Z, Feng F, Zou H, et al. An online survey of the attitude and willingness of Chinese adults to receive COVID-19 vaccine. Hum Vaccin Immunother. (2017) 13:2279–88. doi: 10.1080/21645515.2020.1853449

33. Fan CW, Chen IH, Ko NY, Yen CF, Lin CY, Griffiths MD, et al. Extended theory of planned behavior in explaining the intention to COVID-19 vaccination uptake among mainland Chinese university students: an online survey study. Hum Vaccin Immunother. (2017) 13:3413–20. doi: 10.1080/21645515.2017.1936687

34. Rosiello DF, Anwar S, Yufika A, Adam RY, Islamel MIH, Ismail AE, et al. Acceptance of COVID-19 vaccination at different hypothetical efficacy and safety levels in ten countries in Asia, Africa, and South America. Nat J. (2021) 1. doi: 10.52252/narja.v1i3.55

35. Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. (2021) 326:35–45. doi: 10.1001/jama.2021.8565

36. Omeish H, Najadat A, Al-Azzam S, Tarabin N, Abu Hameed A, Al-Gallab N, et al. Reported COVID-19 vaccines side effects among Jordanian population: a cross sectional study. Hum Vaccin Immunother. (2022) 18:1981086. doi: 10.1080/21645515.2021.1981086

37. Cheng Y, Li T, Zheng Y, Xu B, Bi Y, Hu Y, et al. Self-reported adverse events among Chinese healthcare workers immunized with COVID-19 vaccines composed of inactivated SARS-CoV-2. Hum Vaccin Immunother. (2022) 22:1–7. doi: 10.1080/21645515.2022.2064134

38. National Bureau of statistics of the people's Republic of China. China Statistical Yearbook. Beijing. China Statistics Press (2021). p. 945.